Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
137.25
-3.04 (-2.16%)
Jan 7, 2025, 3:34 PM EST - Market open
Ascendis Pharma Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Ascendis Pharma stock have an average target of 192.07, with a low estimate of 140 and a high estimate of 289. The average target predicts an increase of 39.95% from the current stock price of 137.25.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ASND stock from 14 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 6 | 6 | 7 |
| Buy | 4 | 6 | 6 | 6 | 6 | 6 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 13 | 13 | 13 | 13 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Initiates $196 | Strong Buy | Initiates | $196 | +42.81% | Jan 7, 2025 |
| TD Cowen | TD Cowen | Strong Buy Maintains $160 → $153 | Strong Buy | Maintains | $160 → $153 | +11.48% | Nov 15, 2024 |
| Wedbush | Wedbush | Buy Reiterates $181 | Buy | Reiterates | $181 | +31.88% | Nov 15, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $190 → $180 | Buy | Maintains | $190 → $180 | +31.15% | Nov 15, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $170 | Buy | Reiterates | $170 | +23.87% | Nov 15, 2024 |
Financial Forecast
Revenue This Year
292.43M
from 266.72M
Increased by 9.64%
Revenue Next Year
525.96M
from 292.43M
Increased by 79.86%
EPS This Year
-7.44
from -8.55
EPS Next Year
-4.27
from -7.44
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 386.5M | 786.5M | 1.7B | |||
| Avg | 292.4M | 526.0M | 960.5M | |||
| Low | 256.1M | 383.7M | 690.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 44.9% | 168.9% | 230.6% | |||
| Avg | 9.6% | 79.9% | 82.6% | |||
| Low | -4.0% | 31.2% | 31.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -6.41 | -0.49 | 3.66 | |||
| Avg | -7.44 | -4.27 | -0.17 | |||
| Low | -8.92 | -6.73 | -3.05 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.